NASDAQ:CLLS Cellectis (CLLS) Stock Price, News & Analysis → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Free CLLS Stock Alerts $2.65 -0.02 (-0.75%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.65▼$2.7550-Day Range$2.41▼$3.0952-Week Range$0.96▼$3.77Volume44,022 shsAverage Volume42,603 shsMarket Capitalization$147.29 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Cellectis alerts: Email Address Cellectis MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside315.1% Upside$11.00 Price TargetShort InterestHealthy1.22% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.67Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.89 out of 5 starsMedical Sector432nd out of 938 stocksBiological Products, Except Diagnostic Industry67th out of 148 stocks 3.5 Analyst's Opinion Consensus RatingCellectis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Cellectis has a forecasted upside of 315.1% from its current price of $2.65.Amount of Analyst CoverageCellectis has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.22% of the outstanding shares of Cellectis have been sold short.Short Interest Ratio / Days to CoverCellectis has a short interest ratio ("days to cover") of 13.5, which indicates bearish sentiment.Change versus previous monthShort interest in Cellectis has recently decreased by 6.63%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCellectis does not currently pay a dividend.Dividend GrowthCellectis does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLLS. Previous Next 3.1 News and Social Media Coverage News SentimentCellectis has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cellectis this week, compared to 1 article on an average week.Search Interest3 people have searched for CLLS on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Cellectis to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cellectis insiders have not sold or bought any company stock.Percentage Held by Insiders16.41% of the stock of Cellectis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions63.90% of the stock of Cellectis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cellectis is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cellectis is -1.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCellectis has a P/B Ratio of 0.96. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Cellectis Stock (NASDAQ:CLLS)Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia, as well as a collaboration agreement with AstraZeneca to develop novel cell and gene therapy candidate products. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.Read More CLLS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLLS Stock News HeadlinesMarch 27, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Tuesday TradingMarch 11, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday TradingMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:February 24, 2024 | finance.yahoo.comCellectis S.A. (CLLS)February 20, 2024 | wsj.comCellectis S.A. ADRFebruary 3, 2024 | finance.yahoo.comMonthly information on share capital and company voting rightsJanuary 26, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6%January 16, 2024 | msn.comCellectis draws down second tranche under EIB credit facilityMarch 29, 2024 | Prosper Trading Academy (Ad)Did you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:January 16, 2024 | finance.yahoo.comCellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)December 22, 2023 | finance.yahoo.comCellectis Reports Results from Shareholders Meeting Held on December 22, 2023December 16, 2023 | msn.comCellectis - ADR (CLLS) Price Target Increased by 20.85% to 11.75November 17, 2023 | finance.yahoo.comCellectis’ Shareholders Meeting to be Held on December 22, 2023November 15, 2023 | finance.yahoo.comCellectis Announces the execution of the Subsequent Investment Agreement with AstraZenecaNovember 12, 2023 | morningstar.comCellectis SA ADR CLLSNovember 8, 2023 | finance.yahoo.comCellectis S.A. (NASDAQ:CLLS) Q3 2023 Earnings Call TranscriptNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cellectis SA (CLLS), Agenus (AGEN) and OrthoPediatrics (KIDS)November 6, 2023 | seekingalpha.comCellectis Non-GAAP EPS of -$0.58, revenue of $1.88MNovember 3, 2023 | benzinga.comEarnings Preview: CellectisNovember 2, 2023 | finance.yahoo.comCellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual MeetingNovember 1, 2023 | msn.comCellectis - ADR (CLLS) Price Target Increased by 11.03% to 11.29November 1, 2023 | finance.yahoo.comCellectis to Report Third Quarter 2023 Financial Results on November 6, 2023November 1, 2023 | markets.businessinsider.comCellectis Announces Collaboration Agreement With AstraZeneca; To Receive Up To $245 MlnNovember 1, 2023 | theglobeandmail.comBiotech Shares Soar After AstraZeneca Stake & Research CollaborationNovember 1, 2023 | msn.comWhy Is Cancer Player Cellectis Stock Trading Over 100% Higher Today?November 1, 2023 | msn.comAstraZeneca to invest $245m in French biotech company CellectisNovember 1, 2023 | markets.businessinsider.comWhy Is Cellectis (CLLS) Stock Up 175% Today?See More Headlines Receive CLLS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cellectis and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings12/08/2021Today3/29/2024Next Earnings (Estimated)4/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:CLLS CUSIPN/A CIK1627281 Webwww.cellectis.com Phone(318) 169-1600Fax33-1-81-69-16-06Employees231Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$16.00 Low Stock Price Target$6.00 Potential Upside/Downside+315.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,140,000.00 Net Margins-346.65% Pretax Margin-320.53% Return on Equity-73.03% Return on Assets-32.22% Debt Debt-to-Equity Ratio0.57 Current Ratio2.20 Quick Ratio2.20 Sales & Book Value Annual Sales$25.73 million Price / Sales5.72 Cash FlowN/A Price / Cash FlowN/A Book Value$2.76 per share Price / Book0.96Miscellaneous Outstanding Shares55,580,000Free Float46,463,000Market Cap$147.29 million OptionableOptionable Beta3.13 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Andre Choulika Ph.D. (Age 59)Co-Founder, CEO & Director Comp: $744.02kDr. David j. d. Sourdive Ph.D. (Age 57)Deputy CEO, Executive VP of CMC & Manufacturing and Director Comp: $528.92kDr. Bing C. Wang M.B.A. (Age 47)Ph.D., Chief Financial Officer Valerie CrosPrincipal Financial Officer & Principal Accounting OfficerMr. Jean Charles EpinatChief Technological OfficerDr. Philippe Duchateau Ph.D. (Age 61)Chief Scientific Officer Mr. Stephan Reynier M.Sc. (Age 55)Chief Regulatory & Pharmaceutical Compliance Officer Ms. Marie-Bleuenn Terrier (Age 42)General Counsel & Secretary of the Board of Directors Pascalyne WilsonDirector of CommunicationsMs. Kyung Nam-Wortman (Age 54)Executive VP & Chief Human Resources Officer More ExecutivesKey CompetitorsLENZ TherapeuticsNASDAQ:LENZMolecular PartnersNASDAQ:MOLNBioAtlaNASDAQ:BCABbluebird bioNASDAQ:BLUEaTyr PharmaNASDAQ:LIFEView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 600 shares on 2/15/2024Ownership: 0.000%Oppenheimer & Co. Inc.Bought 11,723 shares on 2/13/2024Ownership: 0.240%Principal Financial Group Inc.Sold 256,973 shares on 2/7/2024Ownership: 0.719%BNP Paribas Financial MarketsBought 4,856 shares on 2/7/2024Ownership: 0.028%Baillie Gifford & Co.Sold 347,366 shares on 1/26/2024Ownership: 1.469%View All Institutional Transactions CLLS Stock Analysis - Frequently Asked Questions Should I buy or sell Cellectis stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CLLS shares. View CLLS analyst ratings or view top-rated stocks. What is Cellectis' stock price target for 2024? 3 brokerages have issued 12-month target prices for Cellectis' stock. Their CLLS share price targets range from $6.00 to $16.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 315.1% from the stock's current price. View analysts price targets for CLLS or view top-rated stocks among Wall Street analysts. How have CLLS shares performed in 2024? Cellectis' stock was trading at $3.08 on January 1st, 2024. Since then, CLLS shares have decreased by 14.0% and is now trading at $2.65. View the best growth stocks for 2024 here. Are investors shorting Cellectis? Cellectis saw a drop in short interest in the month of March. As of March 15th, there was short interest totaling 679,300 shares, a drop of 6.6% from the February 29th total of 727,500 shares. Based on an average daily volume of 50,500 shares, the short-interest ratio is presently 13.5 days. View Cellectis' Short Interest. When is Cellectis' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, April 3rd 2024. View our CLLS earnings forecast. How were Cellectis' earnings last quarter? Cellectis S.A. (NASDAQ:CLLS) announced its earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.80) by $0.02. Cellectis had a negative net margin of 346.65% and a negative trailing twelve-month return on equity of 73.03%. What is André Choulika's approval rating as Cellectis' CEO? 13 employees have rated Cellectis Chief Executive Officer André Choulika on Glassdoor.com. André Choulika has an approval rating of 100% among the company's employees. This puts André Choulika in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 39.0% of employees surveyed would recommend working at Cellectis to a friend. What other stocks do shareholders of Cellectis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectis investors own include Gilead Sciences (gild), Calyxt (CLXT), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Intel (INTC) and Sorrento Therapeutics (SRNE). When did Cellectis IPO? Cellectis (CLLS) raised $129 million in an initial public offering on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray served as the underwriters for the IPO and Oppenheimer was co-manager. Who are Cellectis' major shareholders? Cellectis' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (1.47%), Principal Financial Group Inc. (0.72%), Oppenheimer & Co. Inc. (0.24%), BNP Paribas Financial Markets (0.03%), Citadel Advisors LLC (0.00%) and Cutler Group LLC CA (0.00%). How do I buy shares of Cellectis? Shares of CLLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLLS) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cellectis S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.